Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,162.09 -82.88 (-0.13%) CMC Crypto 200
1,372.28 -45.59 (-3.22%)
Gilead Sciences, Inc. (0QYQ.IL)
| Previous close | 63.92 |
| Open | 62.77 |
| Bid | 61.85 x N/A |
| Ask | 67.58 x N/A |
| Day's range | 62.76 - 65.53 |
| 52-week range | 62.14 - 87.53 |
| Volume | |
| Avg. volume | 63,493 |
| Market cap | 80.76B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 14.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.00 (3.81%) |
| Ex-dividend date | 14 Sept 2023 |
| 1y target est | N/A |
- Business Wire
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
SANTA MONICA, Calif., June 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yescarta and Tecartus® (brexucabtagene autoleucel) at the 2024 European Hematology Association (EHA) Annual Co
- Business Wire
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif., June 06, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry inhibitor bulevirtide as monotherapy and in combination with pegylated interferon alfa-2a (PegIFN), in adults living with compensated chronic hepatitis delta virus (HDV) infection. Published in the New England Journal of Medicine (NEJM), the data demonstrate that the investigational combination of bul
- Business Wire
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
FOSTER CITY, Calif., June 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. The two-year interim analysis includes people living with PBC who participated in any prior clinical studies of seladelpar (legacy studies) and participants from
